Page last updated: 2024-11-06

perfluorosuccinic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Perfluorosuccinic acid (PFSA) is a synthetic perfluorinated carboxylic acid. It is a colorless, odorless, and highly water-soluble compound. PFSA is used as a monomer in the production of fluoropolymers, such as Teflon and Nafion. It is also used in the synthesis of other fluorinated compounds. PFSA has been shown to be resistant to chemical and thermal degradation. It is also known to be a potent inhibitor of the enzyme carbonic anhydrase. PFSA has been studied for its potential applications in various fields, including medicine, electronics, and materials science. PFSA is a highly persistent environmental contaminant that has been detected in the environment. Its persistence and potential toxicity have raised concerns about its environmental impact. PFSA is studied to understand its environmental fate, transport, and potential risks to human health and the environment.'

perfluorosuccinic acid: inhibitor of gluconeogenesis in rat hepatocytes; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID67833
CHEMBL ID84420
SCHEMBL ID508043
MeSH IDM0168672

Synonyms (44)

Synonym
CHEMBL84420
2,2,3,3-tetrafluoro-succinic acid
perfluorosuccinate
nsc3238
perfluorosuccinic acid
377-38-8
succinic acid, tetrafluoro-
tetrafluorosuccinic acid
succinic acid, perfluoro-
butanedioic acid, tetrafluoro-
nsc-3238
wln: qvxffxffvq
perfluoro succinic acid
ai3-19370
einecs 206-820-7
brn 1790197
nsc 3238
2,2,3,3-tetrafluorobutanedioic acid
tetrafluoro-1,4-butanedioic acid
perfluoro-1,4-butanedioic acid
T1621
tetrafluorobutanedioic acid
EN300-93021
2,2,3,3-tetrafluoro-butanedioic acid
unii-is19qhb8ak
butanedioic acid, 2,2,3,3-tetrafluoro-
4-02-00-01926 (beilstein handbook reference)
is19qhb8ak ,
AKOS005173379
FT-0600781
butanedioic acid,2,2,3,3-tetrafluoro-
BP-21140
SCHEMBL508043
perfluorobutanedioic acid
DTXSID8059928
c4h2f4o4
mfcd00042430
tetrafluorosuccinic acid, >/=98%
2,2,3,3-tetrafluorosuccinic acid
AMY14730
AT23283
2,2,3,3-tetrafluorosuccinicacid
BS-43816
Z1203162147
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Genome polyprotein Kd5.20002.90002.90002.9000AID146231
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID146231Dissociation constant for HCV NS3 protease substrate binding site2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Non-peptidic small-molecule inhibitors of the single-chain hepatitis C virus NS3 protease/NS4A cofactor complex discovered by structure-based NMR screening.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (16.67)18.7374
1990's1 (16.67)18.2507
2000's4 (66.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.87 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]